Pathophysiology
Amyloid-beta 42 (from APP via beta-/gamma-secretase) triggers hyperphosphorylated tau and neuronal loss. Risk genes: APOE-e4, APP, PSEN1/2.
Sources: NIA-AA Framework (Alzheimers Dement 2018;14:535); CLARITY-AD (NEJM 2023;388:9)
Presentation
Insidious short-term memory loss, word-finding difficulty, visuospatial deficits progressing to loss of ADLs. Apathy, agitation common.
Diagnosis
MoCA/MMSE; MRI hippocampal atrophy. CSF: low Abeta42, high phospho-tau. Plasma p-tau217 or amyloid-PET confirm biomarker diagnosis.
Management
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for mild-moderate; memantine (NMDA antagonist) added moderate-severe. Anti-amyloid mAbs (lecanemab, donanemab) for early biomarker-positive AD - monitor for ARIA.







